Abpro Holdings granted Nasdaq extension to regain listing compliance

Abpro Holdings, Inc.

Received extension from Nasdaq Hearings Panel to achieve full compliance; deadline not specified.
Completed reverse stock split on Nov 3; plans to increase stockholders' equity and may transfer markets.
Has access to up to $44M in equity financing to fund operations and milestones through 2026.
Achieved ~60% reduction in operating expenses vs prior year; lead candidate ABP-102 on track for 2026 first-in-human trials.
Lead candidate ABP-102 developed with Celltrion; DiversImmune and MultiMab platforms advancing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.